扩散峰度成像联合动态磁敏感对比增强MRI鉴别高级别胶质瘤复发与假性进展
回顾性分析34例高级别胶质瘤术后放化疗后6个月内出现新发或增大强化病灶的患者,病理证实复发22例、假性进展12例。复发组的rMK、rKa、rCBV、rMTT均高于假性进展组(均P<0.05)。rMK与rCBV联合使用将AUC提高至0.924(P<0.001),诊断准确率提高至88.24%。
要点
- 复发组rMK、rKa、rCBV、rMTT均高于假性进展组(均P<0.05)。
- rMK与rCBV为独立鉴别影像分类因子(P=0.006、P=0.009)。
- rMK联合rCBV的AUC为0.924,诊断准确率88.24%。
核心结论
- DKI可能是有价值的无创工具用于鉴别胶质瘤复发与假性进展,与DSC MRI联合使用较任一技术单独可提高评估治疗反应的诊断效能。
研究设计与样本
- 回顾性分析34例高级别胶质瘤患者,术后放化疗后6个月内出现新发和/或增大的强化病灶,病理证实复发22例、假性进展12例;基于增强T1WI上的强化病灶计算DKI与DSC MRI参数。
关键影像表现/征象
- 复发组rMK、rKa、rCBV、rMTT均高于假性进展组(均P<0.05)。
诊断标准与关键数值
- rMK鉴别复发与假性进展的AUC为0.879,诊断准确率82.35%。
- rKa的AUC为0.723,诊断准确率70.59%。
- rCBV的AUC为0.890,诊断准确率82.35%。
- rMTT的AUC为0.765,诊断准确率73.53%。
- 多因素logistic回归显示rMK(P=0.006)与rCBV(P=0.009)为独立影像分类因子;rMK联合rCBV的AUC为0.924(P<0.001),诊断准确率88.24%。
临床应用与阅片要点
- 作者认为DKI可能是鉴别胶质瘤复发与假性进展的有价值无创工具。
- 作者认为DKI与DSC MRI联合使用较任一技术单独可提高评估治疗反应的诊断效能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare the added value of diffusion kurtosis imaging (DKI) with the combination of dynamic susceptibility contrast-enhanced (DSC) MRI in differentiating glioma recurrence from pseudoprogression.
METHODS: Thirty-four patients with high-grade gliomas developing new and/or increasing enhanced lesions within six months after surgery and chemoradiotherapy were retrospectively analyzed. All patients were pathologically confirmed to have recurrent glioma (n = 22) or pseudoprogression (n = 12). The DKI and DSC MRI parameters were calculated based on the enhanced lesions on contrast-enhanced T1WI. ROC analysis was performed on significant variables to determine their diagnostic performance. Multivariate logistic regression was used to determine the best prediction model for discrimination.
RESULTS: The relative mean kurtosis (rMK), relative axial kurtosis (rKa), relative cerebral blood volume (rCBV), and relative mean transit time (rMTT) of glioma recurrence were higher than those of pseudoprogression (all, P < 0.05). The AUCs and diagnostic accuracy were 0.879 and 82.35% for rMK, 0.723 and 70.59% for rKa, 0.890 and 82.35% for rCBV, 0.765 and 73.53% for rMTT, respectively. A multivariate logistic regression model showed a significant contribution of rMK (P = 0.006) and rCBV (P = 0.009) as independent imaging classifiers for discrimination. The combined use of rMK and rCBV improved the AUC to 0.924 (P < 0.001) and the diagnostic accuracy to 88.24%.
CONCLUSION: DKI may be a valuable non-invasive tool in differentiating glioma recurrence from pseudoprogression, and its use in combination with DSC MRI can improve diagnostic performance in assessing treatment response compared with either technique alone.
引用
- Shi W, Qu C, Wang X, et al. Diffusion kurtosis imaging combined with dynamic susceptibility contrast-enhanced MRI in differentiating high-grade glioma recurrence from pseudoprogression. Eur J Radiol. 2021. PMID: 34735828. doi:10.1016/j.ejrad.2021.109941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。